Tanvex BioPharma (TPE:6541) Growth Rank: 7 (As of Sep. 14, 2026) — Near Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TPE:6541 Tanvex BioPharma Inc TPE:6541
47 GF Score
Price NT$30.75
! 3 Warning Signs
View Full Analysis

What is Tanvex BioPharma Growth Rank?

Tanvex BioPharma TPE:6541 -0.16% 47 Growth Rank is 7 as of Sep. 14, 2026, which is at its 10-year median of 7.00. GuruFocus rates TPE:6541 with a GF Score™ of 47/100. The stock has 3 warning signs investors should review.

Tanvex BioPharma has the Growth Rank of 7.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Tanvex BioPharma Growth Rank Related Terms

TPE:6541 vs VRTX, REGN, MRNA: Growth Rank Comparison

For the Biotechnology subindustry, Tanvex BioPharma's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Tanvex BioPharma Growth Rank vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tanvex BioPharma's Growth Rank distribution charts can be found below:

* The bar in red indicates where Tanvex BioPharma's Growth Rank falls into.


TPE:6541
47GF Score
Tanvex BioPharma Inc TPE:6541
Growth Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Growth Rank →
What does a Growth Rank of 7 mean?
Tanvex BioPharma (TPE:6541) has a Growth Rank of 7 as of Sep. 14, 2026. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Tanvex BioPharma and its competitors. This is near median its historical median of 7.00. Over the past decade, Tanvex BioPharma's Growth Rank has ranged from 7.00 to 10.00.
Is Tanvex BioPharma's Growth Rank too high?
Tanvex BioPharma's current Growth Rank of 7 is near median its 10-year median of 7.00. Over the past 10 years, this metric has ranged from a low of 7.00 to a high of 10.00. Overall, Tanvex BioPharma has a GF Score™ of 47/100, reflecting its overall financial health beyond just this single metric.
How does Tanvex BioPharma's Growth Rank compare to VRTX and REGN?
Tanvex BioPharma's Growth Rank of 7 can be compared against companies in the Biotechnology industry. Historically, Tanvex BioPharma's own Growth Rank has ranged from 7.00 to 10.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Growth Rank for a Biotechnology company?
A good Growth Rank depends on the Biotechnology industry context. However, Growth Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Growth Rank mean?
A high Growth Rank can signal that a stock is expensive relative to its fundamentals. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Tanvex BioPharma and its competitors. Tanvex BioPharma's current Growth Rank is 7, which is near median its own 10-year median of 7.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tanvex BioPharma stock overvalued right now?
Tanvex BioPharma (TPE:6541) has a current Growth Rank of 7. The current Growth Rank is 7, which is near median its 10-year median of 7.00. Tanvex BioPharma's overall GF Score™ is 47/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Growth Rank calculated?
Growth Rank is calculated from a company's financial statements. For Tanvex BioPharma (TPE:6541), the current Growth Rank is 7 as of Sep. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Tanvex BioPharma Business Description

Address No. 12-2, Shengyi Road, Section 2, 6th Floor, Hsinchu County, Zhubei, TWN, 106
Tanvex BioPharma Inc is a biopharmaceutical company. It is engaged in the research, development, manufacture, and sale of biosimilar products and contract development and manufacturing of biological medicine. The company's products are used to cure diseases such as Neutropenia, Breast Cancer, Metastatic Colorectal Cancer, and others. Geographically, the company operates in Asia, America, Europe, and Australia. The company generates a majority of its revenue from the USA.
47GF Score

Get the complete analysis for TPE:6541

Growth Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$30.75
Price